ALX Oncology Holdings Inc.

31/07/2024 | Press release | Distributed by Public on 31/07/2024 20:53

ALX Oncology Reports Topline Data From ASPEN 06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2 Positive Gastric Cancer

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.